Gossamer Bio Inc (GOSS NASDAQ) stock market data APIs
$0.1738
-0.01(-5.8%)
as of August 3, 2026
Try our APIs with
free plan!
Gossamer Bio Inc Financial Data Overview
Price chart is built with
Anychart
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
Prev. Close
0.1738
Open
0.1683
High
0.1774
Low
0.1602
52 wk Range
0.114-3.87
Market Cap
84 864 K
Shares Outstanding
489 M
Revenue
55 537 K
Beta
2.006
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Gossamer Bio Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Gossamer Bio Inc data using free add-ons & libraries
Get Gossamer Bio Inc Fundamental Data
Gossamer Bio Inc Fundamental data includes:
- Net Revenue: 55 537 K
- EBITDA: -171 286 000
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-08-04
- EPS/Forecast: -0.1
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Gossamer Bio Inc News
New
Top Biotech Gainers: GOSS To File Seralutinib NDA In Sep, OMER Gains On AZN's Loss, FBRX Acquired
(RTTNews) - Today's top biotech gainers include Entera Bio, following an oversubscribed private placement financing; Gossamer, which is progressing toward a planned Seralutinib NDA submission in Septe...
Gossamer Sets September NDA Filing For Seralutinib In Pulmonary Arterial Hypertension; Stock Up
(RTTNews) - Gossamer Bio, Inc. (GOSS) announced that following a productive Pre-NDA Type B meeting with the U.S. FDA and receipt of the official meeting minutes, the company is moving forward with a p...
Gossamer Bio shares jump after FDA update and seralutinib rights return
Pipette dropping liquid into a test tube ©Adobe Stock Images Gossamer Bio Inc. (NASDAQ:GOSS) shares surged 25% on Monday after the biotechnology company provided a positive regulatory update on its ...
Harbour BioMed Appoints Dr. Luisa Salter-Cid as Scientific Advisor
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, June 10, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and dev...
Get Gossamer Bio Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
